Showing results (1091-1100 of 1,523) with videos related to

Sort By:
Pageof 153
Translational Oncology|October 29, 2021
Prediction of unfavourable response to checkpoint blockade in lung cancer patients through an integrated tumour-immune expression scoreSi-Yang Maggie Liu, Hao Sun, Jia-Ying Zhou, et al.
Brain Research Bulletin|August 31, 2024
Inhibition of the P38 MAPK/NLRP3 pathway mitigates cognitive dysfunction and mood alterations in aged mice after abdominal surgery plus sevofluraneJin-Meng Lv, Yi-Long Gao, Lu-Ying Wang, et al.
CNS Neuroscience & Therapeutics|June 8, 2012
Time course of depression and one-year prognosis of patients with stroke in mainland ChinaNing Zhang, Chun-Xue Wang, An-Xin Wang, et al.
Thoracic Cancer|December 4, 2019
Low frequency of mutation of epidermal growth factor receptor (EGFR) and arrangement of anaplastic lymphoma kinase (ALK) in primary pulmonary lymphoepithelioma-like carcinomaKai Yin, Hui-Bo Feng, Lin-Lin Li, et al.
JCI Insight|January 11, 2022
Predictive value of TCR Vβ-Jβ profile for adjuvant gefitinib in EGFR mutant NSCLC from ADJUVANT-CTONG 1104 trialCunte Chen, Si-Yang Maggie Liu, Yedan Chen, et al.
Journal of the American Heart Association|October 10, 2019
Renal Dysfunction and In-Hospital Outcomes in Patients With Acute Ischemic Stroke After Intravenous Thrombolytic TherapyZhen-Zhen Rao, Hong-Qiu Gu, Xian-Wei Wang, et al.
Lung Cancer (Amsterdam, Netherlands)|August 28, 2016
A randomized, double-blind, phase III study comparing two doses of erlotinib for second-line treatment of current smokers with advanced non-small-cell lung cancer (CurrentS)Egbert F Smit, Yi-Long Wu, Radj Gervais, et al.
Future Oncology (London, England)|March 31, 2022
Phase I/Ib dose-escalation study of avelumab in Chinese patients with advanced solid tumorsYi-Long Wu, Ying Cheng, Huajun Chen, et al.
Cancer|December 6, 2005
Co-overexpression of fibroblast growth factor 3 and epidermal growth factor receptor is correlated with the development of nonsmall cell lung carcinomaAmy L S Tai, Jonathan S T Sham, Dan Xie, et al.
Cancer Immunology, Immunotherapy : CII|March 5, 2023
Neoadjuvant Camrelizumab for Non-Small Cell Lung Cancer: A Retrospective Multicenter, Real-World Study (CTONG2004)Si-Yang Liu, Qixun Chen, Chengzhi Zhou, et al.
Pageof 153